Blood pool contrast agents for cardiovascular MR imaging

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 395-403

  Kroft, Lucia J M ^a   De Roos, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Contrast agents; MR imaging; MRA

Indexed keywords

CONTRAST MEDIUM; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERIC ACID; P 760; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGIOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG SAFETY; EUPHORIA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CONTRAST MEDIA; GADOLINIUM; HUMANS; IRON; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE ANGIOGRAPHY; ORGANOMETALLIC COMPOUNDS; OXIDES;

EID: 0032861527     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<395::AID-JMRI22>3.0.CO;2-P     Document Type: Article

References (79)

1. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992;183:1-11.
2. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998;207:539-544.
3. Mayo-Smith WW, Saini S, Slater G, et al. MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. AJR 1996;166:73-77.
4. Stillman AE, Wilke N, Li D, Haacke M, McLachlan S. Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients. J Comput Assist Tomogr 1996;20:51-55.
5. st ed. Edinburgh: Churchill Livingstone; 1987.
6. Brasch RC. Work in progress: methods of contrast enhancement for NMR imaging and potential applications. Radiology 1983;147:781-788.
7. Wang S-C, Wikström MG, White DL, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. Radiology 1990;175:483-488.
8. Kouwenhoven M. Contrast-enhanced MR angiography: methods, limitations and possibilities. Acta Radiol 1997;38:57-67.
9. Chouly C, Pouliquen D, De Marco G, et al. Development of neutral superparamagnetic iron oxide nanoparticles (MD) as contrast agent for MRI of liver, spleen, and MR lymphography (abstract). Soc Magn Reson Med Berlin, 1992:865.
10. Loubeyre P, Zhao S, Canet E, et al. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J Magn Reson Imaging 1997;7:958-962.
11. Bousquet J-C, Saini S, Stark DD, et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology 1988;166:693-698.
12. Loubeyre P, Canet E, Zhao S, et al. Carboxymethyl-dextrangadolinium-DTPA as a blood-pool contrast agent for magnetic resonance angiography; experimental studies in rabbits. Invest Radiol 1996;31:288-293.
13. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996;3:S356-S358.
14. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901-927.
15. Vexler VS, Berthezene Y, Wilfe CL, et al. Magnetic resonance imaging demonstration of pharmacologic-induced myocardial vasodilatation using a macromolecular gadolinium contrast agent. Invest Radiol 1992;27:935-41.
16. Ogan MD, Schmiedl U, Moseley E, et al. Albumin labeled with Gd-DTPA, an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1987;22:665-671.
17. Fawcett DW. A textbook of histology, 12th ed. New York: Chapman & Hall; 1994.
18. Schmiedl U, Ogan MD, Moseley ME, Brasch RC. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: an experimental study in rats. AJR 1986;147:1263-1270.
19. Vexler VS, Clément O, Brasch RC. A macromolecular contrast agent for magnetic resonance imaging. Effect of molecular weight on blood pharmacokinetics and enhancement patterns for polylysinegadopentetate dimeglumine. Invest Radiol 1994;29:S62-S64.
20. Arthurson G, Wallenius G. The intravascular persistence of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 1964;1:76-80.
21. Arthurson G, Wallenius G. The renal clearance of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 1964;1:81-86.
22. th ed. Utrecht: Wetenschappelijke uitgeverij Bunge; 1987.
23. White DL, Wang S-C, Aicher KP, et al. Albumin-(DTPA-Gd) 15-20: whole-body clearance, plasma clearance, and organ distribution of gadolinium, (abstract). Soc Magn Res Med 1989:2:807.
24. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med 1991;22:282-287.
25. Wilke N, Jerosch-Herold M, Wang Y, et al. Myocardial perfusion reserve: assessment with multisection, quantitative, first-pass MR imaging. Radiology 1997;204:373-384.
26. Fischer SE, Groen JP, Henson RE, et al. Myocardial perfusion assessment of the entire heart (abstract). Int Soc Magn Reson Med Vancouver, 1997;1:478.
27. Wilke N, Jerosch-Herold M. Quantification of myocardial perfusion with magnetic resonance: clinical implications and potentials. In: Higgins CB, Ingwall JS, Pohost GM, editors. Current and future applications of magnetic resonance in cardiovascular disease. Armonk, NY: Futura; 1998.
28. Wendland MF, Saeed M, Yu KK, et al. Inversion recovery EPI of bolus transit in rat myocardium using intravascular and extravascular gadolinium based MR contrast media: dose effects on peak signal enhancement. Magn Reson Med 1994;32:319-329.
29. Wilke N, Kroll K, Merkle H, et al. Regional myocardial blood volume and flow: first-pass MR imaging with polylysine-Gd-DTPA. J Magn Reson Imaging 1995;5:227-237.
30. Bursteln D, Taratuta E, Manning WJ. Factors in myocardial "perfusion" imaging with ultrafast MRI and Gd-DTPA administration. Magn Reson Med 1991;20:299-305.
31. Matheijssen NAA, Louwerenburg HW, Van Rugge FP, et al. Comparison of ultrafast dipyridamole magnetic resonance imaging with dipyridamole SestaMIBI SPECTfor detection of perfusion abnormalities in patients with one-vessel coronary artery disease: assessment by quantitative model fitting. Magn Reson Med 1996;35:221-228.
32. Keijer JT, Van Rossum AC, Van Eenige MJ, et al. Semiquantltation of regional myocardial blood flow in normal human subjects by flrst-pass magnetic resonance imaging. Am Heart J 1995;130:893-901.
33. Wilke N, Simm C, Zhang J, et al. Contrast-enhanced first-pass myocardial perfusion imaging: correlation between myocardial blood flow in dogs at rest and during hyperemia. Magn Reson Med 1993;29:485-497.
34. Kroft LJM, Doornbos J, Van der Geest RJ, Benderbous S, De Roos A. Infarcted myocardium in pigs: MR imaging enhanced with slow-interstitial-diffusion gadolinium-compound P760. Radiology 1999;212:467-473.
35. Wilke N, Jerosch-Herold M, Stillman AE, et al. Concepts of myocardial perfusion imaging in magnetic resonance imaging. Magn Reson Q 1994;10:249-286.
36. Eichenberger AC, Shuiki E, Kochli VD, et al. Ischemic heart disease: assessment with gadolinium-enhanced ultrafast MR imaging and dipyridamole stress. J Magn Reson Imaging 1994;4:425-431.
37. Saeed M, Van Dijke CF, Mann JS, et al. Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. J Magn Reson Imaging 1998;8:561-567.
38. Lim T-H, Lee JH, Gong G, Park S-J, Lee I. Significance of magnetic resonance signal enhancement in evaluation of myocardial infarction in cats. Invest Radiol 1995;30:306-314.
39. Schwitter J, Saeed M, Wendland MF, et al. Infuence of severity of myocardial injury on distribution of macromolecules: extravascular versus intravascular gadolinium-based magnetic resonance contrast agents. J Am Coll Cardiol 1997;30:1086-1094.
40. De Roos A, Van Rossum AC, Van der Wall EE, et al. Reperfused and nonreperfused myocardial infarction: diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology 1989;172:717-720.
41. Ovize M, Revel D, De Lorgeril M, et al. Quantitation of reperfused myocardial infarction by Gd-DOTA-enhanced magnetic resonance imaging. Invest Radiol 1991;26:1065-1070.
42. Lima JAC, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92:1117-1125.
43. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-772.
44. Inoue S-I, Marakami Y, Ochiai K, et al. The contributory role of interstitial water in Gd-DTPA-enhanced MRI in myocardial infarction. J Magn Reson Imaging 1999;9:215-219.
45. Wendland MF, Saeed M, Lauerman K, et al. Alterations in Tl of normal and reperfused infarcted myocardium after Gd-BOPTA versus Gd-DTPA on inversion recovery EPI. Magn Reson Med 1997;37:448-456.
46. Axel L. Blood flow effects in magnetic resonance imaging. In: Kressel HY, editor. Magnetic resonance annual. New York: Raven Press; 1986.
47. Laufler RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR anglography. Radiology 1998;207: 529-538.
48. Parmelee DJ, Walovitch RC, Ouellet HS, Randall B, Laufier B. Preclinical evaluations of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 1997;32:741-747.
49. McMurry T, Tyeklár Z, Midelfort K, et al. Synthesis and physical properties of MS-325, the first small molecule blood pool contrast agent for MRI (abstract). Int Soc Magn Reson Med 1997:1572.
50. Bluemke DA, Borman T. MR angiography of the carotid arteries: Preliminary results using an intravascular contrast agent (MS-325) (abstract). Int Soc Magn Reson Med Sidney, 1998:495.
51. Stuber M, Botnar RM, McConnell MV, et al. Coronary artery imaging with the intravascular contrast agent MS-325 (abstract). Int Soc Magn Reson Med Sidney, 1998:316.
52. Saeed M, Wendland MF, Engelbrecht M, Sakuma H, Higgins CB. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities. Eur Radiol 1998;8:1047-1053.
53. Hilfiker PR, Zimmermann-Paul GG, Schmidt M, et al. Intestinal and peritoneal bleeding: detection with an intravascular contrast agent and fast three-dimensional MR imaging. Preliminary experience from an experimental study. Radiology 1998;209:769-774.
54. Taylor AM, Panting JR, Keegan J, et al. Use of the intravascular contrast agent NC100150 injection in spin-echo and gradient-echo imaging of the heart. J Cardiovasc Magn Reson 1999;1:23-32.
55. Tarlo KS, Jerosch-Herold M, Mansoor A, et al. NC 100150 injection: a new intravascular MR contrast agent for morphological and functional assessment of the heart (abstract). J Cardiovasc Magn Reson 1999;1:65.
56. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 1997;7:209-214.
57. Taylor AM, Panting JR, Keegan J, et al. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging 1999;9:220-227.
58. Stillman AE, Wilke N, Jerosch-Herold M. Use of an intravascular contrast agent to improve MR cine myocardial-blood pool definition in man. J Magn Reson Imaging 1997;7:765-767.
59. Panting JR, Taylor AM, Gatehouse PD, et al. First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection (abstract). J Cardiovase Magn Reson 1999;1:82.
60. Wilke N, Jerosch-Herold J, Muehler A, et al. 24-Gd-DTPA-cascade-polymer; a novel intravascular relaxation contrast agent for cardiac MR first pass imaging (abstract). Proc Soc Magn Res San Francisco, 1994;1:112.
61. Jerosch-Herold M, Wilke NM, Wang YA, et al. Comparative assessment of myocardial perfusion with intravascular and extracellular contrast agents. RSNA Chicago. Radiology, 1998;209(suppl):228.
62. -1 7. An animal study original investigation. Invest Radiol 1998;33:699-708.
63. Li D, Zheng J, Weinmann H-J, et al. Comparison of intravascular and extravascular contrast agents in coronary artery imaging (abstract). Int Soc Magn Reson Med. Sidney, 1998;1:17.
64. Adam G, Neuerberg J, Spüntrup E, Mühler A, Scherer K, Günther RW. Dynamic contrast-enhanced MR imaging of the upper abdomen: enhancement properties of gadobutrol, gedolinium-DTPA-polylysine, and gadolinium-DTPA-cascade-polymer. Magn Reson Med 1994;32:622-628.
65. Roberts HC, Saeed M, Roberts TPL, et al. Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability. J Magn Reson Imaging 1997;7:331-338.
66. Su M-Y, Mühler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 1998;39:259-269.
67. Arteaga C, Canet E, Ovize M, Janier M, Revel D. Myocardial perfusion assessed by subsecond magnetic resonance imaging with a paramagnetic macromolecular contrast agent. Invest Radiol 1994; 29:S54-S57.
68. Corot C, Schaefer M, Beauté S, et al. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA; a new paramagnetic dextran polymer. Acta Radiol 1997;38:91-99.
69. Casali C, Janier M, Canet E, et al. Evaluation of Gd-DOTA-labeled dextran polymer as an intravascular MR contrast agent for myocardial perfusion. Acad Radiol 1998;5:S214-S218.
70. Kroft LJM, Doornbos J, Van der Geest RJ, De Roos A. Blood pool contrast agent CMD-A2-Gd-DOTA enhanced MR imaging of infarcted myocardium in pigs. J Magn Reson Imaging 1999;10:170-177.
71. Kroft LJM, Doornbos J, Benderbous S, De Roos A. Equilibrium phase MR angiography of the aortic arch and abdominal vasculature with the blood pool contrast agent CMD-A2-Gd-DOTA in pigs. J Magn Reson Imaging 1999;9:777-785.
72. Marchal G, Bosmans H, Van Hecke P, et al. MR angiography with gadopentetate dimeglumine-polylysine: evaluation in rabbits. AJR 1990;155:407-411.
73. Böck JC, Pison U, Kaufmann F, Felix R. Gd-DTPA-polylysine-enhanced pulmonary time-of-flight MR angiography. J Magn Reson Imaging 1994;4:473-476.
74. Saeed M, Wendland MF, Masui T, et al. Myocardial infarction: assessment with an intravascular MR contrast medium. Radiology 1991;180:153-160.
75. Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press W-R, Weinmann H-J. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for maagnetic resonance imaging. Invest Radiol 1991;26:969-974.
76. Niendorf HP, Houstein J, Cornelius I, Alhassan A, Clauβ W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991;22:222-228.
77. Weinmann H-J, Press W-R, Gries HT. Tolerance of extracellular contrast agents for magnetic resonance imaging. Invest Radiol 1990;25:S49-S50.
78. Almén T. The etiology of contrast medium reactions. Invest Radiol 1994;29:S37-S45.
79. De Haën C, Morisetti A, Bertani F, Tirone P. The factor time in acute intravenous toxicity studies of contrast media. Invest Radiol 1994; 20;S108-S110.